Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine
It's an exciting time to be in the biotech and pharmaceutical industries. To read the full piece, please click here.
Rgenix CEO Masoud Tavazoie was recently interviewed for an article in The Pharma Letter. To read the full piece, please click here. ×
For Immediate Release New York, NY – April 27, 2017 – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today the appointment of Roger Waltzman, M.D., M.B.A. as its Chief Medical Officer. Dr. Waltzman
Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic
Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic First-in-Class Cancer Therapeutic Targets the Liver X Receptor (LXR)-ApoE Pathway Identified Using Rgenix’s Discovery Platform NEW YORK CITY, N.Y., January 6, 2017 – Rgenix, Inc.,